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Abstract Human malignant autosomal recessive osteo-
petrosis (ARO) is a genetically heterogeneous disorder
caused by reduced bone resorption by osteoclasts. Muta-
tions in the CLCN7 gene are responsible not only for a
substantial portion of ARO patients but also for other forms
of osteopetrosis characterized by different severity and
inheritance. The lack of a clear genotype/phenotype cor-
relation makes genetic counseling a tricky issue for
CLCN7-dependent osteopetrosis. Here, we characterize the
first homozygous interstitial deletion in 16p13.3, detected
by array comparative genomic hybridization in an ARO
patient of Jordanian origin. The deletion involved other
genes besides CLCN7, while the proband displayed a
classic ARO phenotype; however, her early death did
not allow more extensive clinical investigations.
The identification of this novel genomic deletion involving
a large part of the CLCN7 gene is of clinical relevance,
especially in prenatal diagnosis, and suggests the possi-
bility that this kind of mutation has been underestimated so
far. These data highlight the need for alternative approa-
ches to genetic analysis also in other ARO-causative genes.
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Autosomal recessive osteopetrosis (ARO) is a rare inher-
ited disease characterized by increased bone density. Since
the original identification of the first gene involved in its
pathogenesis, our view of the genetics of human ARO has
become much more complicated: at least six genes
(TCIRG1, CLCN7, OSTM1, PLEKHM1, RANKL, and
RANK) can be affected, and each gene presents a wide
spectrum of mutations with very few cases of recurrent
changes [1]. Recently, the identification of two large
genomic deletions in the TCIRG1 gene [2, 3] has high-
lighted the limits of standard methods for mutational
analysis and the possibility that similar mutations could be
present also in other known ARO genes.
In the last decade array comparative genomic hybrid-
ization (a-CGH) has become widely used in clinical prac-
tice as it allows the detection of submicroscopic
chromosome imbalanced aberrations, which can be
responsible for several pathologic conditions [4].
Here, we describe a homozygous contiguous gene
deletion in chromosome 16p13.3 found using this
approach. The deletion affects 19 out of 25 exons in the
CLCN7 gene and two additional genes and is responsible
for the disease in a Jordanian ARO patient.
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Materials and Methods
Samples
DNA samples were obtained from the patient and her
parents after receiving informed consent. Genomic DNA
was extracted from peripheral blood lymphocytes by
standard techniques (overnight incubation in 19 Tris
EDTA/0.4 % SDS/10 mg/mL proteinase K). The investi-
gation was approved by the Comitato Etico Indipendente
Istituto Clinico Humanitas IRCCS.
TCIRG1 and CLCN7 Gene Mutation Analysis
Each gene was studied by individual amplification and
direct automated sequencing of exons and intron–exon
boundaries as previously described [3, 5].
Array CGH
Array CGH (a-CGH) was performed on an Agilent
microarray platform (Santa Clara, CA). The 4x44K whole-
genome microarray slides were custom-designed using
Agilent’s eArray 5.0 online software (http://www.agilent.
com) enriched with 5,467 probes for the CLCN7 and
TCIRG1 gene regions, with an average probe spacing of
125 bp. Sample preparation, labelling, and microarray
hybridization were performed according to Agilent CGH
Enzymatic Protocol version 6.2.1. Slides were acquired
using the Agilent G2565CA scanner and analyzed using
Agilent Feature Extraction 9.5.1 software. The a-CGH
profile was extrapolated using Agilent Genomic Work-
bench 6.5.0.18 software.
Characterization of the Deletion
The deletion was characterized by PCR analysis and direct
sequencing using a forward primer in intron 3 of the N-
acetylglucosamine-1-phosphate transferase, gamma subunit
(GNPTG) gene (50-AGGGGTGAGTGGAATGTCAG-30)
and a reverse primer in intron 6 of the CLCN7 gene (50-AA
CCTCAGGAGGAGCAGACA-30).
Results and Discussion
The patient was born from consanguineous parents of
Arabic descent. She presented soon after birth with
increased bone density on X-ray (Fig. 1), severe anemia
requiring transfusions, pancytopenia, hepatosplenomegaly,
failure to thrive, and chronic diarrhea due to infections and
pseudomembranous colitis, suggesting a partial, secondary
immune deficit; however, lymphocyte subsets in the
periphery were within the normal range, and marked
thrombocytopenia did not allow further investigations.
Laboratory analysis showed hypophosphatemia, hypocal-
cemia, and congenital hypothyroidism, which was treated
with L-thyroxine (25 lg daily).
Ophthalmoscopy revealed pale optic disks and macula
scarring of both eyes, while the optic nerve canals were
symmetric and within normal limits at a CT scan per-
formed at 4 months of age.
The severe condition of the patient did not allow further
investigation; she eventually died of sepsis at 6 months of
age. No autopsy was performed.
The patient was investigated for mutations in the TCIRG1
gene and subsequently in CLCN7 since these two genes
contribute to about 65 % of ARO patients. No mutation was
found in the TCIRG1 gene, while lack of amplification of
exons 7–25 of the CLCN7 gene in the patient raised the
possibility of the presence of a large homozygous genomic
deletion, possibly extending beyond the gene itself. a-CGH
identified a deletion on chromosome 16p13.3, involving the
CLCN7 gene. A large number of probes showed a highly
negative fluorescence log ratio (-1 to -4/-?), highlighting
homozygous deletion for the entire affected region [6]. The
proximal breakpoint of the deletion was mapped between
probes A_16_P57375613 and A_16_57375614 localized at
1,408,559 and 1,409,150 bp, respectively, while the distal
breakpoint was between probes A_16_33816661 and
Fig. 1 X-ray of the left arm of the proband, demonstrating the
osteopetrotic phenotype
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A_16_3381666 at 1,509,177 and 1,509,209 bp, respectively
(hg19 assembly) (Fig. 2).
The deletion encompassed several genes: exons 4–11 of
GNPTG, the entire coding sequence of the unkempt
homolog (Drosophila)-like (UNKL) gene, exons 7–25 of
CLCN7, and additional regions not fully characterized
(C16orf91 and CCDC154) (Fig. 3a). Subsequently, in
order to exactly define the breakpoints, a series of forward
and reverse primers were designed on the basis of the
genomic localization of the a-CGH probes flanking the
deletion. A PCR product of 1,350 bp was obtained only in
the patient and in her parents but not in a healthy control,
using a forward primer in intron 3 of the GNPTG gene and
a reverse primer in intron 6 of the CLCN7 gene. Direct
sequencing of the amplicon allowed us to determine the
exact size of the deletion, which was 101,621 bp
(CLCN7:c.594?193_oGNPTG:c.178?6298; the mutation
nomenclature conforms to www.hgvs.org/mutnomen).
The presence of a chimeric RNA or of protein products
deriving from the truncated genes (CLCN7 and GNPTG)
could not be investigated due to the lack of an appropriate
sample from the patient (only DNA was available).
In order to unravel the molecular mechanisms respon-
sible for this large genomic deletion, we performed in
silico analysis (http://repeatmasker.org) and identified
repeated sequences within 100 bp from the breakpoints,
namely, a LINE element in intron 3 of the GNPTG gene
and a simple repeat in intron 6 of the CLCN7 gene
(Fig. 3b), possibly involved in the recombination event.
The short arm of chromosome 16 has been extensively
studied since it contains a large number of genes. It is often
involved in pathological and nonpathological rearrange-
ments, and other interstitial deletions have been reported in
the heterozygous state [7–9]. In some cases CLCN7 is
involved, too [7, 10]; however, to our knowledge none of
them has been associated with an osteopetrotic phenotype,
even though heterozygous mutations in CLCN7 are
responsible for autosomal dominant osteopetrosis type II
(ADOII, MIM 166600). This further confirms our previous
suggestion [5] that heterozygous null mutations do not
interfere with normal bone resorption and that haploin-
sufficiency is not causative for ADOII. In agreement with
this hypothesis, the proband’s parents did not report any
symptom possibly related to osteopetrosis.
One of the genes involved in the deletion herein
described, GNPTG, is known to cause mucolipidosis III
gamma (MLIIIc, MIM 252605), a slowly progressive
lysosomal storage disorder characterized by short stature,
cardiomegaly, developmental delay, and skeletal abnor-
malities. In early childhood, X-rays usually reveal dysos-
tosis multiplex, which worsens with age, giving rise to
generalized osteopenia. The proband did not display any
obvious clinical feature related to MLIIIc; however, the
severity of the osteopetrotic phenotype and the early death
due to secondary immunodeficiency could have overcome
mucolipidosis manifestations.
Regarding the UNKL gene, so far there is no evidence of
its involvement in pathological conditions. Preliminary in
Fig. 2 Array CGH profile for
16p13.3 enriched region. The
deletion is shown by the
software as light green bars as a
negative gap of probe
fluorescence log ratios (between
-1 and -4/-?). The position
of the probes identifying the
proximal and distal breakpoints
is shown by arrows
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vitro studies have recently suggested that it could be linked
to physiological control of the SWI/SNF chromatin
remodeling complexes; however, its physiological signifi-
cance is not completely elucidated [11].
Contiguous gene deletions usually lead to syndromic
diseases; nonetheless, our patient showed a classic osteo-
petrotic phenotype, and the only additional peculiar feature
was congenital hypothyroidism. Its etiology was not further
characterized either clinically or genetically; in fact, the
differential diagnosis did not alter the treatment decision,
which aimed at compensating the hormone deficit in order
to prevent neurological deterioration [12]. Of note, the
current knowledge of the genetic basis of congenital
hypothyroidism is extremely poor; therefore, it cannot be
excluded that in this case the genetic determinants of
hypothyroidism lie in the deleted region, even though we
could not provide any direct evidence.
Conventional methods for mutational analysis in ARO
patients are generally based on PCR amplification and
direct sequencing of each exon and exon–intron junctions;
therefore, they can fail to detect large genomic deletions in
the heterozygous state. This fact is particularly relevant in
CLCN7-dependent ARO. So far, we have molecularly
characterized more than 250 ARO patients and widely
demonstrated that TCIRG1 and OSTM1 gene mutations are
recessive in nature [1]. On the contrary, CLCN7 mutations
give rise to a wide range of clinical pictures, even in the
same family. Although monoallelic, dominant ‘‘benign’’
and biallelic ‘‘severe’’ recessive osteopetrosis are usually
distinct, several patients with intermediate severity have
been described [5, 13]. In this regard, the recognition of
nonobvious heterozygous deletions could shed further light
on this disorder. In addition, it is extremely relevant for
genetic counseling of family members and, in particular,
for a correct prenatal diagnosis; indeed, failure to detect
this type of mutation can lead to the misinterpretation of
the single variant sequence identified, which can be erro-
neously considered as a homozygous mutation when
masked by a coincident exonic deletion.
Recent findings [2, 3] together with the present data
suggest that large genomic deletions could be underesti-
mated, and adequate approaches of genetic screening
should be developed. This is particularly relevant for
osteopetrosis, in which the results of molecular analysis
have a significant impact on patient management.
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Fig. 3 Characterization of the deletion. a Schematic representation
of the chromosomal region with the genes involved in the deletion
here depicted by the dashed rectangle. For GNPTG and CLCN7 genes
the intron–exon structure is shown. b Upper panel Sequence of the
amplicon; the precise breakpoint lies in the 4 bp highlighted in gray
and shared by both intron 3 of the GNPTG gene and intron 6 of
CLCN7. Lower panel Sequence of breakpoint junctions aligned to the
reference sequences. The position of distal and proximal reference
comes from hg19 assembly; repeats located within 100 bp from the
breakpoints are shown in lowercase. The regions of homology where
recombination may have occurred are highlighted in gray
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